TTX-080
TTX-080 is a humanized monoclonal antagonistic antibody targeting human leukocyte antigen G (HLA-G) . TTX-080 exerts anti-tumor activity by relieving HLA-G-mediated immune suppression. TTX-080 is promising for research of solid tumors such as metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (mHNSCC) [1].
Product Specifications
UNSPSC
12352203
Target
Others
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Ulahannan S V, et al. Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma[J]. 2024.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
H6100-50N-ML650 100 µL
HLA Class 2 Antigen DRA, NT (HLA Class II Histocompatibility Antigen DR alpha Chain, HLA-DRA, HLA-DRA1, FLJ51114, MHC Class II Antigen DRA, MLRW) (MaxLight 650) discontinued
Sign In for Pricing
View Details 
D-1115.0025 25.0g
Fmoc-Leu-Wang resin (200-400 mesh, 0.50-1.00 mmol/g)
Sign In for Pricing
View Details